These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20496257)

  • 1. Autotaxin and lipid signaling pathways as anticancer targets.
    Braddock DT
    Curr Opin Investig Drugs; 2010 Jun; 11(6):629-37. PubMed ID: 20496257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
    Federico L; Pamuklar Z; Smyth SS; Morris AJ
    Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.
    van Meeteren LA; Brinkmann V; Saulnier-Blache JS; Lynch KR; Moolenaar WH
    Cancer Lett; 2008 Aug; 266(2):203-8. PubMed ID: 18378389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
    Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
    J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
    Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN
    Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
    Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance.
    Samadi N; Bekele R; Capatos D; Venkatraman G; Sariahmetoglu M; Brindley DN
    Biochimie; 2011 Jan; 93(1):61-70. PubMed ID: 20709140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors.
    Xu X; Yang G; Zhang H; Prestwich GD
    Prostaglandins Other Lipid Mediat; 2009 Sep; 89(3-4):140-6. PubMed ID: 19682598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.
    Zhang H; Xu X; Gajewiak J; Tsukahara R; Fujiwara Y; Liu J; Fells JI; Perygin D; Parrill AL; Tigyi G; Prestwich GD
    Cancer Res; 2009 Jul; 69(13):5441-9. PubMed ID: 19509223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.
    North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL
    Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
    East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATX-LPA receptor axis in inflammation and cancer.
    Liu S; Murph M; Panupinthu N; Mills GB
    Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
    Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
    ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors.
    Tabchy A; Tigyi G; Mills GB
    Nat Struct Mol Biol; 2011 Feb; 18(2):117-8. PubMed ID: 21289650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
    Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
    J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
    Zhang R; Wang J; Ma S; Huang Z; Zhang G
    BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autotaxin: a protein with two faces.
    Tania M; Khan MA; Zhang H; Li J; Song Y
    Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation and biological activities of the autotaxin-LPA axis.
    van Meeteren LA; Moolenaar WH
    Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophospholipids in the limelight: autotaxin takes center stage.
    Moolenaar WH
    J Cell Biol; 2002 Jul; 158(2):197-9. PubMed ID: 12135981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of autotaxin/lysophospholipase D activity.
    Morris AJ; Smyth SS
    Methods Enzymol; 2007; 434():89-104. PubMed ID: 17954243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.